Denali Therapeutics Inc. (DNLI) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Denali Therapeutics Inc. (DNLI)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

18.76

-0.83 (-4.24%)

At close: Jan 14, 2025, 3:59 PM

18.17

-3.14%

Pre-market Jan 15, 2025, 05:39 AM EST

undefined% (undefined)

Bid	18.12
Market Cap	2.70B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.76
PE Ratio (ttm)	-6.8
Forward PE	n/a
Analyst	Buy

Ask	21.5
Volume	729,882
Avg. Volume (20D)	880,286
Open	19.85
Previous Close	19.59
Day's Range	18.52 - 19.90
52-Week Range	14.56 - 33.33
Beta	undefined

About DNLI

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 8, 2017

Employees 390

Stock Exchange NASDAQ

Ticker Symbol DNLI

Website https://www.denalitherapeutics.com

Analyst Forecast

According to 13 analyst ratings, the average rating for DNLI stock is "Buy." The 12-month stock price forecast is $32, which is an increase of 70.58% from the latest price.

Buy 92.31%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Denali Therapeutics Inc. is scheduled to release its earnings on Feb 25, 2025, before market opens.
Analysts project revenue of $12.58M, reflecting a n/a YoY growth and earnings per share of -0.91, making a 5.81% increase YoY.

Why Price Moved

1 month ago · Source

+6.73%

Denali Therapeutics shares are trading higher. The... Unlock content with Pro Subscription

7 months ago · Source

+9.81%

Denali Therapeutics shares are trading shares are trading higher after the FDA selected DNL126 for participation in the Support for clinical Trials Advancing Rare disease Therapeutics Pilot Program.

News

5 days ago · seekingalpha.com

Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains

Denali Therapeutics Inc.'s DNL343 failed to meet the primary endpoint in the phase 2/3 HEALY ALS trial, but potential biomarker analyses in 2025 may offer a path forward. Despite the trial setback in ...

6 days ago · zacks.com

DNLI's Hunter Syndrome Drug Gets Breakthrough Therapy Designation

Denali obtains Breakthrough Therapy Designation for its experimental candidate, tividenofusp alfa (DNL310), for the treatment of pateints with Hunter syndrome.

1 week ago · zacks.com

Denali's ALS Study Fails to Meet Primary and Secondary Endpoints

DNLI's DNL343 fails to achieve the primary and secondary endpoints, as observed from an analysis of Regimen G of the phase II/III HEALEY ALS platform trial.

1 week ago · reuters.com

Denali Therapeutics ALS drug fails in mid-stage trial

Denali Therapeutics said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial in patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disea...

1 week ago · benzinga.com

Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic

William Blair has initiated coverage on Denali Therapeutics Inc DNLI, a company focused on developing drugs for neurodegenerative diseases.

1 month ago · zacks.com

Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock?

1 month ago · zacks.com

Denali Starts Dosing in Phase II Parkinson's Disease Study

DNLI begins dosing in the phase IIa study on BIIB122 in approximately 50 participants with Parkinson's disease and LRRK2 pathogenic mutations confirmed by genetic testing.

2 months ago · seekingalpha.com

Denali Has A Neurodegenerative Edge Despite Market Skepticism

Denali Therapeutics' unique blood-brain barrier technology and strategic partnerships offer a significant edge in the challenging neurodegenerative disease landscape. The company's strong cash positio...

2 months ago · zacks.com

Denali Q3 Earnings Miss Estimates, Pipeline Progress Encouraging

DNLI reports a wider-than-expected loss in the third quarter of 2024. Nonetheless, the pipeline progress has been encouraging.

2 months ago · zacks.com

Denali Therapeutics Inc. (DNLI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Denali Therapeutics (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.